Oryzon Genomics S.A. (ORYZF)
OTCMKTS · Delayed Price · Currency is USD
3.600
+0.240 (7.14%)
At close: Jan 27, 2026
Oryzon Genomics Revenue
Oryzon Genomics had revenue of $8.63M in the twelve months ending September 30, 2025, down -45.45% year-over-year. In the year 2024, Oryzon Genomics had annual revenue of $7.62M, down -51.43%.
Revenue (ttm)
8.63M
Revenue Growth
-45.45%
P/S Ratio
33.22
Revenue / Employee
183.70K
Employees
47
Market Cap
286.80M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7.62M | -8.07M | -51.43% |
| Dec 31, 2023 | 15.69M | -1.09M | -6.50% |
| Dec 31, 2022 | 16.78M | 4.70M | 38.97% |
| Dec 31, 2021 | 12.07M | 425.74K | 3.66% |
| Dec 31, 2020 | 11.65M | 112.98K | 0.98% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 292.21M |
| Vaxart | 148.20M |
| Silence Therapeutics | 25.83M |
| Nuo Therapeutics | 2.61M |
| Northwest Biotherapeutics | 937.00K |
| ZIVO Bioscience | 209.03K |
| Arch Biopartners | 198.11K |
Oryzon Genomics News
- 7 weeks ago - ORYZON Expands Global Patent Protection for Iadademstat with Grant Decision in Japan Covering Combinations with PD-1/PD-L1 Inhibitors - GlobeNewsWire
- 2 months ago - ORYZON Announces the Voting Results of December 2025 Extraordinary General Shareholders' Meeting - GlobeNewsWire
- 3 months ago - ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2025 - GlobeNewsWire
- 3 months ago - ORYZON Announces First‑Patient‑In (FPI) in RESTORE Phase Ib Trial of Iadademstat in Sickle Cell Disease - GlobeNewsWire
- 3 months ago - ORYZON to Participate in Upcoming Events in November - GlobeNewsWire
- 4 months ago - ORYZON Receives Feedback From the FDA in Response to the Submitted Phase III Protocol in Borderline Personality Disorder - GlobeNewsWire
- 4 months ago - ORYZON Strengthens Patent Portfolio for iadademstat with European Grant Decision Covering Combinations with PD1/PD-L1 Inhibitors - GlobeNewsWire
- 5 months ago - ORYZON Strengthens Patent Portfolio for Iadademstat and Vafidemstat with New Decisions to Grant - GlobeNewsWire